 CARLSBAD, Calif., Aug. 20, 2021 GLOBE NEWSWIRE -- Palisade Bio, Inc. Nasdaq: PALI Palisade Bio or the Company, a latestage biopharma company advancing therapies for acute and chronic gastrointestinal GI complications, today announces a new private investment of approximately 5.2 million from the Yuma Regional Medical Center YRMC, an Arizonabased, notforprofit hospital providing highquality, patientcentered care. The funds will be used to advance the clinical development of Palisades lead oral liquid drug candidate LB1148, which is being developed to accelerate the return of bowel function after surgery and to reduce postsurgical adhesions. 